ABL Diagnostics specializes in the development of software for collecting and processing medical databases, measuring the quality of care, diagnosing infectious diseases (AIDS, viral hepatitis and tuberculosis) by genotyping, and providing decision support for doctors and nurses, virology and microbiology laboratories, and researchers dealing with patients suffering from chronic and complex diseases. Export accounts for 69.7% of net sales.

Employees

Sector

Medical Equipment, Supplies & Distribution

Calendar

07-03 - Ex-dividend date - 0.11 EUR

More about the company

Quotes

Date	Price	Change	Volume
19/06/26	2.640 €	+9.09%	12,464
18/06/26	2.420 €	+0.83%	20,504
17/06/26	2.400 €	0.00%	9,299
16/06/26	2.400 €	-4.76%	20,402
15/06/26	2.520 €	-7.35%	28,332

Real-time Euronext Paris

More quotes

Income Statement and Estimates

More financial data

Annual profits - Rate of surprise

Company calendar

Market Closed - Euronext Paris Other stock markets 16:55:00 19/06/2026 BST			5-day change	1st Jan Change
2.640 ^EUR	+9.09%		-2.94%	-12.00%

06-12	Abl Diagnostics Sa and Cdl Pharma Secure Multi-Year International Contract of Up to Eur 2.7 Million Through 2031	CI
06-12	ABL Diagnostics Signs Multi-year Contract to Provide Clinical Trial Services	MT

Market Cap	42.42M 48.66M 39.29M 36.78M 68.98M 4.59B 69.4M 466M 181M 2.26B 183M 179M 7.85B	P/E 2024	123x	P/E 2025	50x
Enterprise Value	43.36M 49.73M 40.15M 37.59M 70.5M 4.69B 70.92M 476M 185M 2.31B 187M 183M 8.02B	EV / Sales 2024	7,098,474x	EV / Sales 2025	6,185,843x
Free-Float	2.52%	Yield 2024	2.03%	Yield 2025	3.67%

06-12	Abl Diagnostics Sa and Cdl Pharma Secure Multi-Year International Contract of Up to Eur 2.7 Million Through 2031	CI
06-12	ABL Diagnostics Signs Multi-year Contract to Provide Clinical Trial Services	MT
06-12	ABL Diagnostics Secures Multi-Year Contract with CDL Pharma
06-10	ABL Diagnostics Offers to Buy Texcell	MT
06-05	ABL divests block of ABL Diagnostics shares
06-01	ABL Diagnostics Société anonyme Provides Earnings Guidance for the Fiscal Year Ending December 31, 2026	CI
05-18	ABL Diagnostics Société anonyme Proposes Dividend for the Financial Year Ended December 31, 2025, Payable on July 7, 2026	CI
05-06	ABL Diagnostics Société anonyme Reports Earnings Results for the Full Year Ended December 31, 2025	CI
11-14	Abl Diagnostics Appoints Eurobio Scientific as Exclusive Distributor for Its Vela Product Line in A Targeted Segment of the French Market	CI
01/10/25	ABL Diagnostics Société anonyme Reports Earnings Results for the Half Year Ended June 30, 2025	CI
05/08/25	ABL Diagnostics Société anonyme announced that it expects to receive funding from Alumni Capital Management	CI
08/05/25	ABL Diagnostics Société anonyme announces Annual dividend, payable on July 01, 2025	CI
05/05/25	ABL Diagnostics Société anonyme Reports Earnings Results for the Full Year Ended December 31, 2024	CI

06-18	ABL Diagnostics: Growth Trajectory Confirmed and Strong Upside Potential Identified	BU
06-12	ABL Diagnostics and CDL Pharma Secure a Multi-year International Contract of up to €2.7 Million Through 2031	BU
06-10	ABL Diagnostics (ABLD) Announces the Submission of a Takeover Bid for Texcell France	BU
06-09	ABL Diagnostics: Ordinary and Extraordinary General Meeting of June 30, 2026 – Terms for Making Available or Consulting Preparatory Documents	BU
06-05	ABL Diagnostics: Sale of a new block of shares by its main shareholder ABL	BU

ABL Diagnostics Share Price

Stocks

ABLD

FR001400AHX6

Medical Equipment, Supplies & Distribution

Valuation: ABL Diagnostics

Chart: ABL Diagnostics

Latest news : ABL Diagnostics

Press Releases: ABL Diagnostics

News in other languages: ABL Diagnostics

Quotes and Performance

Course Extremes

Managers and Directors: ABL Diagnostics

Latest insider transactions

Other Medical Equipment, Supplies & Distribution

Financials

Company Profile

Quotes

Income Statement and Estimates

Annual profits - Rate of surprise

06-18	ABL Diagnostics : trajectoire de croissance confirmée et fort levier de revalorisation identifié
06-12	ABL Diagnostics remporte un contrat pluriannuel avec CDL Pharma
06-12	ABL Diagnostics et CDL Pharma remportent un contrat international pluriannuel pouvant atteindre 2,7 M€ jusqu’en 2031
06-10	ABL Diagnostics (ABLD) annonce le dépôt d’une offre de reprise de Texcell France
06-09	ABL Diagnostics : Assemblée Générale Ordinaire et Extraordinaire du 30 juin 2026 – Modalités de mise à disposition ou de consultation des documents préparatoires

1 day	+9.09%
1 week	-2.94%
Current month	-22.81%
1 month	-22.35%
3 months	-21.43%
6 months	-14.84%
Current year	-12.00%

1 week	2.36	2.88
1 month	2.36	3.8
Current year	2.12	5
1 year	2.12	5.75
3 years	2.12	9.7
5 years	1.99	26
10 years	1.28	26

Director	Title	Age	Since
Noemie Sadoun CHM	Chairman	-	-
Laure Raffaelli BRD	Director/Board Member	-	-
Deborah Szafir BRD	Director/Board Member	-	-

Date	Insider	Type	Main position	Quantity	% Market Cap.
06-01	Advanced Biological Laboratories SA	Sell	Company	-57,692	0.3580%
05-26	Advanced Biological Laboratories SA	Sell	Company	-51,900	0.3221%
03-16	Advanced Biological Laboratories SA	Sell	Company	54,745	0.3397%

Add to a list 0 selected To use this feature you must be a member Log in Sign up	Change	5-day change	1-year change	3-year change	Capi.($)
ABL DIAGNOSTICS	+9.09%	-2.94%	-51.56%	-59.38%	48.66M
ABBOTT LABORATORIES	-0.10%	+0.26%	-33.23%	-16.75%	154B
MEDTRONIC PLC	+1.54%	-1.07%	-7.45%	-11.00%	102B
HOYA CORPORATION	-4.45%	+3.12%	+59.84%	+56.09%	56.51B
CENCORA, INC.	-1.90%	-3.49%	-8.40%	+48.53%	52.89B
BECTON, DICKINSON AND COMPANY	+1.67%	-1.55%	-14.60%	-44.33%	39.67B
MEDLINE INC.	-1.32%	-1.83%	-	-	30.39B
DEXCOM, INC.	+1.74%	-3.85%	-10.54%	-44.30%	27.96B
WEST PHARMACEUTICAL SERVICES, INC.	+1.35%	-0.26%	+50.47%	-9.42%	23.17B
TERUMO CORPORATION	-1.53%	+1.14%	-15.03%	-5.42%	20.35B
Average	+0.61%	-1.46%	-3.39%	-9.55%	50.69B
Weighted average by Cap.	-0.27%	-1.24%	-6.19%	-2.71%

	2024	2025
Net sales	5.87 6.73 5.44 5.09 9.54 635.2 9.6 64.49 24.99 312.65 25.27 24.73 1.09K	7.97 9.14 7.38 6.91 12.95 862.05 13.03 87.52 33.92 424.31 34.29 33.56 1.47K
Net income	285K 327K 264K 247K 464K 30.86M 466K 3.13M 1.21M 15.19M 1.23M 1.2M 52.75M	987K 1.13M 914K 855K 1.6M 107M 1.61M 10.84M 4.2M 52.56M 4.25M 4.16M 182M
Net Debt	2.02M 2.32M 1.87M 1.75M 3.29M 219M 3.31M 22.24M 8.62M 108M 8.71M 8.53M 374M	933K 1.07M 864K 809K 1.52M 101M 1.53M 10.25M 3.97M 49.68M 4.02M 3.93M 173M